A Bioactive Nanocomposite Integrated Specific TAMs Target and Synergistic TAMs Repolarization for Effective Cancer Immunotherapy
Overview
Authors
Affiliations
Reactive oxygen species (ROS) generated from photosensitizers exhibit great potential for repolarizing immunosuppressive tumor-associated macrophages (TAMs) toward the anti-tumor M1 phenotype, representing a promising cancer immunotherapy strategy. Nevertheless, their effectiveness in eliminating solid tumors is generally limited by the instability and inadequate TAMs-specific targeting of photosensitizers. Here, a novel core-shell integrated nano platform is proposed to achieve a coordinated strategy of repolarizing TAMs for potentiating cancer immunotherapy. Colloidal mesoporous silica nanoparticles (CMSN) are fabricated to encapsulate photosensitizer-Indocyanine Green (ICG) to improve their stability. Then ginseng-derived exosome (GsE) was coated on the surface of ICG/CMSN for targeting TAMs, as well as repolarizing TAMs concurrently, named ICG/CMSN@GsE. As expected, with the synergism of ICG and GsE, ICG/CMSN@GsE exhibited better stability, mild generation of ROS, favorable specificity toward M2-like macrophages, enhancing drug retention in tumors and superior TAMs repolarization potency, then exerted a potent antitumor effect. , experiment results also confirm the synergistic suppression of tumor growth accompanied by the increased presence of anti-tumor M1-like macrophages and maximal tumor damage. Taken together, by integrating the superiorities of TAMs targeting specificity and synergistic TAMs repolarization effect into a single nanoplatform, ICG/CMSN@GsE can readily serve as a safe and high-performance nanoplatform for enhanced cancer immunotherapy.
Invasion and metastasis in cancer: molecular insights and therapeutic targets.
Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.
PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.
Yang Q, Wang Y, Wang S, Song A, Wang W, Zhang L Bioact Mater. 2025; 47:283-294.
PMID: 39925708 PMC: 11803166. DOI: 10.1016/j.bioactmat.2025.01.018.
An Q, Wang D, Huang L, Chen X, Wang C Front Pharmacol. 2024; 15:1498728.
PMID: 39498338 PMC: 11532140. DOI: 10.3389/fphar.2024.1498728.
Zhao B, Lin H, Jiang X, Li W, Gao Y, Li M Theranostics. 2024; 14(12):4598-4621.
PMID: 39239509 PMC: 11373634. DOI: 10.7150/thno.97096.